Microchip Technology (MCHP) fell 5.3% on November 6, 2026, to $61.43, extending a five-day slide of 20.6% after the company's fiscal Q2 earnings beat but Q3 guidance trailed estimates. The stock is now 24.6% below its October 5 peak of $81.49 and trades below its 50-day and 200-day averages, with the weekly trend firmly down. The balance of evidence for the next 2–6 weeks leans negative, with high conviction, as the daily trend aligns with the weekly downtrend and the stock lags both the S&P 500 and the semiconductor sector.
Why it matters
Microchip reported fiscal Q2 2027 net sales of $1.622 billion, up 42.2% year-over-year and above the high end of guidance, with non-GAAP EPS of $0.97 beating estimates. Yet the stock dropped 4% on the news because Q3 revenue guidance of $1.573–$1.623 billion trailed analyst expectations, as Investing.com reported. The market had priced in a beat; the forward-looking weakness is what mattered.
The 5-day move of -20.6% is not just a company story. The sector ETF SOXX fell 23.0% over the same period, and the S&P 500 dropped 4.7%, so MCHP actually outperformed its sector by 2.4 percentage points. The stock's relative weakness is more visible over 50 days: it lags SPY by 14.6% and SOXX by 1.4%, confirming that the downtrend is stock-specific, not just a beta effect.
The debate among analysts is split. On one side, Yahoo! Finance notes an upgrade to Zacks Rank #2 (Buy) with consensus estimates up 18.3% over three months. On the other, the mean analyst price target of $105.92 implies 42% upside from current levels, but targets range from $75 to $135, a wide spread that reflects uncertainty. The stock is 42% below the mean target, but that gap is typical in a downtrend and not a signal by itself.
What the evidence says
The long-term thesis is broken. The stock is below its 40-week average, and the weekly trend is down. The 50-day average ($74.91) and 200-day average ($79.62) are both above price, and the stock is 40.3% below its 52-week high. The structure holds below $63.54, a swing zone where sellers have repeatedly appeared on rallies. The trend would end only on a weekly close above $68.42, another swing zone.
For the next 2–6 weeks, the balance of evidence leans negative with high conviction (3 of 4 conviction points). The daily trend runs with the weekly downtrend, and the stock lags both SPY and SOXX over 50 days. The RSI at 32.55 is oversold, but that alone does not reverse a downtrend. The strongest case against the bearish reading is that after a one-day drop of more than 5%, the stock was higher a month later 70.9% of the time (151 cases), with a median 1-month gain of 5.38%. That historical bounce tendency is real, but it does not outweigh the trend alignment and relative weakness; it is why conviction is not 4 of 4.
Levels that matter
In a downtrend, the structure holds below $63.54, the swing zone where sellers have shown up on rallies. The trend would end on a weekly close above $68.42, another swing zone. Below $63.54, the next support is $60.00 (round), then $50.00, and the 52-week low at $49.02.
The downside breakout level is a daily close below $60.00. From there, the first target is the 52-week low at $49.02, with a stop at $64.62 (based on the swing zone plus a quarter of ATR). That gives a reward-to-risk of 2.4 to 1, which does not meet the 3-to-1 threshold that makes a breakout worth the risk. To reach 3 to 1, the target would need to be lower or the stop tighter; as it stands, the math is not compelling.
What would change the picture
A weekly close above $68.42 would end the downtrend and shift the picture to neutral or positive. The only non-price fact that could do that is a clear reversal in the semiconductor cycle, such as a major customer order or a sector-wide rally that lifts SOXX and MCHP together. Until then, the evidence points down.
What to watch
- Next earnings: February 4, 2027. The key number is Q4 revenue guidance, not the reported quarter.
- Sector moves: SOXX is the primary driver; a stabilization in semiconductors would likely precede any MCHP bounce.
- Valuation: the stock is 42% below the mean analyst target of $105.92, but targets range widely from $75 to $135, so the consensus is not a reliable floor.